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Semi-parametric maximum likelihood estimates
for ROC curves of continuous-scale tests
Xiao Hua Zhou † ∗ and Hua Zhen Lin ∗‡
Summary
In this paper, we propose a semi-parametric maximum likelihood estimate of an ROC curve that
satisfies the property of invariance of the ROC curve. In our simulation studies, we demonstrate that
the proposed estimator has the best performance among all the existing semi-parametric estimators
considered here. Finally, we illustrate the application of the proposed estimator using a real data
set.
Key words: ROC curves; Sensitivity and specificity; Semi-parametric maximum likelihood
estimators.
1 Introduction
When the response of a diagnostic test is continuous, its diagnostic accuracy is best represented by
the receiver operating characteristic (ROC) curve (Pepe, 2003; Zhou et al., 2002). Let F1 and F0
denote distribution functions of the test result Y1 for a diseased subject and the test result Y0 for a
non-diseased subject, respectively. Then, the ROC curve of the test can be written as
ROC(u) = 1− F1(F−10 (1− u)), (1)
where F−10 is the inverse function of F0, and u is the false positive rate (FPR) corresponding to
a cut-off point for positivity. It is well-known that the ROC curve of a test must be invariant to
any monotone increasing transformation of test results, a fundamental property of an ROC curve.
Hence, any sensible estimation methods should have this property. In the statistical literature,
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many parametric, semi-parametric, and non-parametric methods have been proposed for estimating
an ROC curve. In general, pure parametric methods do not possess the invariance property; the
empirical non-parametric and smoothing non-parametric methods have the property of invariance
(Hsieh and Turnbull, 1996; Peng and Zhou, 2004). However, the jagged form of the empirical
ROC curve estimator can result in underestimating the true ROC curve as the true ROC curve
is a smooth function, and the intensive computation and challenging bandwidth selection of the
smoothing non-parametric estimators may effect their application in practice.
An intermediate strategy between pure parametric and non-parametric methods is a semi-
parametric approach. The most commonly used semi-parametric method is to assume a parametric
form for the ROC curve, but avoid making any additional parametric assumptions about the dis-
tributions of test results. This type of semi-parametric methods has the property of invariance. In
this paper, we focus on this type of semi-parametric methods.
We assume that the ROC curve has the parametric form,
ROC(u) = G(α0 + α1H−1(u)), (2)
where G and H are some known cumulative distribution functions. The most common choice for G
and H is the binormal form, G = H = Φ, where Φ is the cumulative distribution function of the
standard normal random variable.
Under the binormal model, several methods have been proposed by Metz et al. (1998), Alonzo
and Pepe (2002), Pepe and Cai (2004), Zou et al. (2000), and Cai and Moskowitz (2004), respectively.
The first approach, proposed by Metz et al. (1998) and denoted by MHS, is to first categorize
continuous test data into ordinal-scale categorical data and then to apply the maximum likelihood
method to estimate the parameters in the binormal model by assuming the ordinal-scale data follow
a multinomial distribution. The second approach, proposed by Alonzo and Pepe (2002) and denoted
by AP, is to estimate the ROC curve by using procedures for fitting generalized linear models to
binary data. The third approach, proposed by Pepe and Cai (2004) and denoted by PC, is to first
write the ROC curve as the distribution of placement values and then to estimate the ROC curve by
maximizing the pseudo likelihood function of the estimated placement values. The fourth method,
proposed by Zou et al. (2000) and denoted by ZH, is to use rank data to estimate the ROC curve
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by assuming semi-parametric distributions for test results of diseased and non-diseased subjects.
One limitation of these methods is that none are a truly maximum likelihood (ML) estimator, and
hence they do not possess the optimal property associated with ML estimators. Recently, Cai and
Moskowitz (2004), denoted by CM, have proposed a maximum profile likelihood approach to estimate
the ROC curve; however, their computation algorithm requires an input of initial values of a large
number of nuisance parameters, which may be difficult in practice when the sample size is large.
In this paper, we propose a new profile likelihood approach to estimate the ROC curve. Our
method has a smaller number of nuisance parameters to estimate and hence may be more efficient
than the Cai and Moskowitz method. Furthermore, our estimator can be computed by using an
algorithm that is based on a recursive relationship among the nuisance parameters, without speci-
fying initial values for a large number of nuisance parameters. Our MLE is asymptotically normal,
and our extensive simulation studies show the proposed method is more efficient, more robust, and
simpler to compute than the existing estimators.
Since the binormal model is the most commonly used form for an ROC curve, from now on we
assume that the true ROC curve is defined by
ROC(u) = Φ(α0 + α1Φ−1(u)), (3)
where Φ−1(·) is the inverse of the cumulative distribution of the standard normal distribution.
Equivalently, we can derive model (3) by assuming there exists an unknown monotone increasing
function g(.) such that g(Y0) has the standard normal distribution and g(Y1) has a normal distri-
bution with mean µ and standard deviation σ. The resulting ROC curve satisfies model (3) with
α0 = µ/σ and α1 = 1/σ.
This paper is organized as follows. In Section 2, we propose a semi-parametric maximum like-
lihood estimator of an ROC curve and an algorithm for computing it. In Section 3, we develop
asymptotic properties for the resulting estimator. In Section 4, we perform simulation studies to
asses efficiency and robustness of our estimator relative to the existing semi-parametric estimators
and to verify the validity of the asymptotic inferences in finite samples. In Section 5, we illustrate
the application of our method in a real example.
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2 Semi-parametric maximum likelihood estimate
Data available for making inferences consist of a random sample of size n1 from the diseased pop-
ulation with the unknown cumulative distribution function F1, {Y1j , j = 1, · · · , n1}, and a random
sample of size n0 from the non-diseased population, {Y0i, i = 1, · · · , n0}, with the unknown cumu-
lative distribution function F0. Denote n = n0 + n1.
Let f0 and f1 be the density functions of F0 and F1, respectively. Then, the likelihood function
of observations Y0i, i = 1, · · · , n0, and Y1j , j = 1, · · · , n1, is given by
L =
n0∏
i=1
f0(Y0i)
n1∏
j=1
f1(Y1j). (4)
Under model (3), we know that there exists a unknown monotone increasing function g(.) such
that g(Y0) has the standard normal distribution and g(Y1) has a normal distribution with mean
µ and standard deviation σ. Therefore, we have that f0(y) = φ(g(y))g′(y) and f1(y) = φ(−α0 +
α1g(y))α1g′(y). Hence we can write the likelihood function (4) as
L =
n0∏
i=1
φ(g(Y0i))g′(Y0i)
n1∏
j=1
φ(−α0 + α1g(Y1j))α1g′(Y1j), (5)
where φ(x) is the standard normal density function. Consequently, the ML estimation of ROC curve
parameters α0 and α1 requires simultaneous estimation of the unknown function g. In what follows
we write 4g(x) as the jump of g(·) at x if g is discrete at x and the derivative of g(·) at x if g(·) is
continuous at x. We seek to maximize the function Ln given by
Ln =
n0∏
i=1
φ(g(Y0i))4g(Y0i)
n1∏
j=1
φ(−α0 + α1g(Y1j))α14g(Y1j). (6)
Using a standard argument in the nonparametric maximum likelihood estimation (Murphy and Van
der Vaart, 2000), we can restrict the MLE, ĝ, of g to be the maximiser of the likelihood function
Ln over all discrete functions g and show that the MLE, ĝ, has to be a discrete function that only
jumps at observations Y0i, i = 1, · · · , n0, and Y1j , j = 1, · · · , n1. Denote the distinct ordered test
results from the combined sample, Y0i’s and Y1j ’s, by Y ∗(1) < · · · < Y ∗(I∗n), where I
∗
n is the number of
distinct values among Y0i’s and Y1j ’s. Then MLE ĝ of g jumps only at Y ∗(1) < · · · < Y ∗(I∗n), and we
can write the likelihood function (6) as follows:
Ln =
I∗n∏
r=1
(
φ(g(Y ∗(r)))4g(Y ∗(r))
)k∗r (
φ(−α0 + α1g(Y ∗(r)))α14g(Y ∗(r))
)`∗r
, (7)
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where frequency counts k∗r = #{Y0i = Y ∗(r), i = 1, · · · , n0} and `∗r = #{Y1j = Y ∗(r), j = 1, · · · , n1},
corresponding to non-diseased and diseased subjects at distinct ordered test results.
When g = ĝ, g jumps only at Y ∗(1) < · · · < Y ∗(I∗n), for r = 1, . . . , I
∗
n, we have 4Φ(g(Y ∗(r))) =
Φ(g(Y ∗(r)))−Φ(g(Y ∗(r−1))) and 4Φ(−α0+α1g(Y ∗(r))) = Φ(−α0+α1g(Y ∗(r)))−Φ(−α0+α1g(Y ∗(r−1))),
where g(Y ∗(0)) = −∞. In addition, 4Φ(g(Y ∗(r))) = φ(g(Y ∗(r)))4g(Y ∗(r)) and 4Φ(−α0 + α1g(Y ∗(r))) =
φ(−α0 +α1g(Y ∗(r)))α14g(Y ∗(r)). Hence, with C∗r = g(Y ∗(r)), C∗0 = −∞, and C∗I∗n = +∞, we can write
(7) as
Ln =
I∗n∏
r=1
(
Φ(C∗r )− Φ(C∗r−1)
)k∗r (Φ(−α0 + α1C∗r )− Φ(−α0 + α1C∗r−1))`∗r (8)
when g = ĝ. Therefore ML estimation of ROC curve parameters α0 and α1, which are of primary in-
terest, requires simultaneous estimation of the I∗n−1 number of nuisance parameters, C∗1 , · · · , C∗I∗n−1.
Using the same idea as in Metz (1998), we note that some of the jump points of ĝ, Y ∗(r)’s, can
be ignored for estimating α0 and α1, which means we can obtain ML estimates of α0 and α1 with
fewer nuisance parameters. We state the results in Conclusion 1 below.
Denote
D(Y ∗(r)) =

2 if #{Y0i = Y ∗(r), i = 1, · · · , n0} > 0 and #{Y1j = Y ∗(r), j = 1, · · · , n1} > 0
1 if #{Y0i = Y ∗(r), i = 1, · · · , n0} > 0 and #{Y1j = Y ∗(r), j = 1, · · · , n1} = 0
0 if #{Y0i = Y ∗(r), i = 1, · · · , n0} = 0 and #{Y1j = Y ∗(r), j = 1, · · · , n1} > 0
and
< =
{
Y ∗(r) : D(Y
∗
(r)) = D(Y
∗
(r+1)) ≤ 1, 1 ≤ r ≤ I∗n − 2
}
.
Each jump point in < has the same disease status as its next contiguous jump point. Here, <
includes all jump points of a contiguous sequence with the same disease status except the last point
in the sequence.
Conclusion 1. The maximum likelihood estimates of α0 and α1 can be determined by some
estimating equations that don’t depend on those nuisance parameters C∗r = g(Y
∗
(r))’s whose Y
∗
(r)
belongs to <.
See Appendix A.1 for a proof of Conclusion 1. A practical consequence of the conclusion is that
we can ignore the jump points in < for estimating α0 and α1.
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After deleting the points in <, we denote the remaining jump points of ĝ by Y(1) < · · · < Y(In−1)
and let Cr = g(Y(r)) for 1 ≤ r ≤ In − 1, C0 = −∞ and CIn = +∞. The MLE of θ = (α0, α1)T and
C = (C1, · · · , CIn−1)T can be obtained by maximizing
Ln(θ,C) =
In∏
r=1
(Φ(Cr)− Φ(Cr−1))kr (Φ(−α0 + α1Cr)− Φ(−α0 + α1Cr−1))`r , (9)
which is essentially (8) with I∗n replaced by In. Here, for 2 ≤ r ≤ In − 1, kr = #{Y(r−1) < Y0i ≤
Y(r), i = 1, · · · , n0} and `r = #{Y(r−1) < Y1j ≤ Y(r), j = 1, · · · , n1}; k1 = #{Y0i ≤ Y(1), i =
1, · · · , n0}, `1 = #{Y1j ≤ Y(1), j = 1, · · · , n1}, kIn = #{Y0i > Y(In−1), i = 1, · · · , n0}, and `In =
#{Y1j > Y(In−1), j = 1, · · · , n1}.
It should be noted that the function (9) is the same as the likelihood proposed by Metz et al
(1998). However, Metz et al. (1998) have obtained the likelihood from a parametric viewpoint
by assuming that test results could be partitioned into a contingency table with a fixed number
of categories and that the resulting contingency table follows a multinomial distribution. In fact,
the number of categories, In, increases with the sample size, and as a result, the assumed standard
multinomial distribution does not hold. Therefore, although Metz et al. (1998) have derived a correct
likelihood function form, their justification is not right. Furthermore, to maximize the likelihood
function (9) with respect to θ and C, Metz et al. (1998) have used the standard Newton-Raphson
iterative method that requires inversion of an (In + 1) × (In + 1) matrix; this computation can
become a problem if In is large. Due to this concern, they have proposed an alternative algorithm
by reducing the number of jump points, In− 1, in an ad hoc way. Hence, their resulting estimate of
θ is no longer a ML estimate, and our simulation studies show the ad hoc computation method can
lead to some loss of efficiency.
We propose a new algorithm for finding ML estimates based on the function (9). We propose a
two-stage iterative procedure for estimating θ and C, alternating the parametric and nonparametric
estimation steps. Our idea is from Kvam and Samaniego (1994) on the nonparametric estimation.
Given θ, we can find the MLE of C by maximizing the likelihood function (9) with respect to
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C. The MLE of C must satisfy the following (In − 1) score equations:
∂ log{Ln(θ,C)}
∂C1
= k1
φ(C1)
Φ(C1)
− k2 φ(C1)Φ(C2)− Φ(C1)
+α1`1
φ(−α0 + α1C1)
Φ(−α0 + α1C1) − α1`2
φ(−α0 + α1C1)
Φ(−α0 + α1C2)− Φ(−α0 + α1C1) = 0,
∂ log{Ln(θ,C)}
∂Cr
= kr
φ(Cr)
Φ(Cr)− Φ(Cr−1) − kr+1
φ(Cr)
Φ(Cr+1)− Φ(Cr)
+α1`r
φ(−α0 + α1Cr)
Φ(−α0 + α1Cr)− Φ(−α0 + α1Cr−1)
−α1`r+1 φ(−α0 + α1Cr)Φ(−α0 + α1Cr+1)− Φ(−α0 + α1Cr) = 0, 2 ≤ r ≤ In − 2,
∂ log{Ln(θ,C)}
∂CIn−1
= kIn−1
φ(CIn−1)
Φ(CIn−1)− Φ(CIn−2)
− kIn
φ(CIn−1)
1− Φ(CIn−1)
+α1`In−1
φ(−α0 + α1CIn−1)
Φ(−α0 + α1CIn−1)− Φ(−α0 + α1CIn−2)
−α1`In
φ(−α0 + α1CIn−1)
1− Φ(−α0 + α1CIn−1)
= 0. (10)
Given θ, the existence and uniqueness of the MLE of C are established in the following result,
and a proof is given in the Appendix A.2.
Conclusion 2. Given θ, the Ĉ that satisfies the score equations in (10) is unique.
Inspection of (10) shows that finding the MLE of C in a closed form is a challenge. Hence, an
iterative algorithm is required. However, the standard Newton-Raphson iteration requires inversion
of an (In − 1)× (In − 1) matrix, and this computation can become a problem if In is large.
Now we make use of the uniqueness in Conclusion 2 to solve the equations (10). Note that
`rkr = 0, for 1 ≤ r ≤ In; `r`r+1 = 0 and krkr+1 = 0 for 1 ≤ r ≤ In − 1. Suppose that we have
selected an initial value of C1, Cˇ1. Then from the first equation of (10), we obtain an estimate, Cˇ2,
of C2,
Cˇ2 =

α0
α1
+ 1α1Φ
−1
(
Φ(−α0 + α1Cˇ1) + α1`2φ(−α0+α1Cˇ1)Φ(Cˇ1)k1φ(Cˇ1)
)
if k2 = 0
Φ−1
(
Φ(Cˇ1) +
k2Φ(−α0+α1Cˇ1)φ(Cˇ1)
α1`1φ(−α0+α1Cˇ1)
)
if `2 = 0
.
For r = 2, · · · , In − 2, using the latest estimates, Cˇr−1 and Cˇr, of Cr−1 and Cr, we solve the rth
equation of (10) to obtain the following estimate of Cr+1:
Cˇr+1 =

α0
α1
+ 1α1Φ
−1
(
Φ(−α0 + α1Cˇr) + α1`r+1φ(−α0+α1Cˇr)(Φ(Cˇr)−Φ(Cˇr−1))krφ(Cˇr)
)
if kr+1 = 0
Φ−1
(
Φ(Cˇr) +
kr+1φ(Cˇr)(Φ(−α0+α1Cˇr)−Φ(−α0+α1Cˇr−1))
α1`rφ(−α0+α1Cˇr)
)
if `r+1 = 0
.
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Hence, given the initially chosen value of C1, Cˇ1, we can obtain the estimates, Cˇ2, . . . , CˇIn−1, of
C2, . . . , CIn−1 by solving the first In − 2 equations in (10). Now we are left to check whether these
estimates also satisfy the last equation in (10),
Λ(CˇIn−2, CˇIn−1) = 0, (11)
where Λ(CIn−2, CIn−1) =
∂
∂CIn−1
log{Ln(θ,C)}. If Λ(CˇIn−2, CˇIn−1) = 0, the estimates, Cˇr, r =
1, . . . , In − 1, are the unique solution to equation (10). If Λ(CˇIn−2, CˇIn−1) 6= 0, we need to update
the initially chosen value estimate, Cˇ1, and repeat the whole estimation process until the last equation
in (10) is satisfied.
Let θ0 be the true value of θ and g0 be the true function of g. Denote Cr0 = g0(limn→∞ Y(r)) and
C0 = (C10, · · · , C(In−1)0)T . In the following Conclusion 3, we establish the relationship between
C1 and Λ(CIn−2, CIn−1) to help in updating the initially chosen value, Cˇ1. We provide a proof for
Conclusion 3 in the Appendix A.3.
Conclusion 3. Let θn = θ0+op(1). For any initially chosen value Cˇ1 of C1, we let Cˇ2, . . . , CˇIn−1
be the corresponding solution to the first (In − 2) equations in (10). Then, when n is large enough,
1. if Cˇ1 < C10, then Cˇr < Cr0 for r = 2, · · · , In − 1, and
Λ(CˇIn−2, CˇIn−1) =
∂
∂CIn−1
log{Ln(θ,C)}|C=Cˇ,θ=θn > 0;
2. if Cˇ1 > C10, then Cˇr > Cr0 for r = 2, · · · , In − 1, and
Λ(CˇIn−2, CˇIn−1) =
∂
∂CIn−1
log{Ln(θ,C)}|C=Cˇ,θ=θn < 0,
where Cˇ = (Cˇ1, . . . , CˇIn−1).
The results of Conclusion 3 provide a mechanism for updating the initially chosen value Cˇ1.
If Λ(CˇIn−2, CˇIn−1) > 0, we should increase our initially chosen value, Cˇ1. On the other hand, if
Λ(CˇIn−2, CˇIn−1) < 0, we should decrease our initially chosen value, Cˇ1.
Given C, we can estimate θ by maximizing (9). We next outline the two-stage iterative procedure
for estimating θ and C.
• Step 1. We combine data from the diseased and non-diseased samples and order test results
in the combined sample, replace each test result by its true disease status. As a result, we
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create a sequence of disease statuses for the combined sample. Denote the number of different
sequences with the same consecutive disease status by In. Then, count the number of elements
in each sequence, denoted by k = {k1, · · · , kIn |
∑In
r=1 kr = n0} for non-diseased subjects
and ` = {`1, · · · , `In |
∑In
s=1 `s = n1} for diseased subjects. For example, if we have data
{5.38, 2.1, 4.5} for non-diseased subjects and {12.5, 10.4, 16.8, 5.1, 13.5} for diseased subjects,
the ordered test results in the combined sample are {2.1, 4.5, 5.1, 5.38, 10.4, 12.5, 13.5, 16.8}, and
their corresponding disease statuses are {no, no, di, no, di, di, di, di}, where no and di indicate
a non-diseased and diseased subject, respectively. Thus, in the above notation, we have In = 4
and k1 = 2, k2 = 0, k3 = 1, k4 = 0 and `1 = 0, `2 = 1, `3 = 0, `4 = 4.
• Step 2. Given values of α0, α1, we estimate C1, · · · , CIn−1 by solving (10).
• Step 3. Given estimates of C1, · · · , CIn−1, we estimate α0 and α1 by maximizing (9) with
respect to α0 and α1.
• Step 4. Repeat Steps 2 and 3 until two successive values for (α0, α1, C1, · · · , CIn−1) converge.
The convergent values α̂0, α̂1, Ĉ1, · · · , ĈIn−1 are the estimates of α0, α1, C1, · · · , CIn−1.
3 Asymptotic distribution theory
Our final estimate θ̂ of θ is a profile likelihood estimate, which maximizes the profile likelihood for
θ given by
PL(θ) = Ln(θ, Ĉ(θ)),
where Ĉ(θ) maximizes the likelihood Ln(θ,C) for a fixed value of θ. This estimator is a function
of the test values only through their ranks. Using the results on the properties of maximum profile
likelihood estimates derived by Murphy and Van der Varrt (2000), we can show that θ̂ is fully
efficient and n1/2(θ̂ − θ0) converges in distribution to a zero-mean bivariate normal random vector
with covariance matrix Σ, where
Σ =
{
− lim
n→∞
∂2 logLn(θ,C)
n∂θ∂θ′
+
(
lim
n→∞
∂2 logLn(θ,C)
n∂θ∂C′
)
×
(
lim
n→∞
∂2 logLn(θ,C)
n∂C∂C′
)−1(
lim
n→∞
∂2 logLn(θ,C)
n∂C∂θ′
)}−1
|θ=θ0,C=C0 . (12)
9
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Based on the estimates of α0 and α1, we can estimate the ROC curve by R̂OC(u) = Φ(α̂0 +
α̂1Φ−1(u)). Using the Taylor series expansion and the asymptotically normal result of θ̂, we can show
that n1/2
(
R̂OC(u)−ROC(u)
)
converges in distribution to a zero-mean normal random variable
with variance
φ2(α00 + α10Φ−1(u))
 1
Φ−1(u)
T Σ
 1
Φ−1(u)
 ,
where Σ is defined by (12), α00, and α10 are the true values of α0 and α1, respectively.
4 Numerical studies
In this section we conduct several simulation studies to (1) determine if our estimator is more efficient
than the five existing estimators, (2) assess the robustness of our estimator against the departure
from the binormal model, and (3) evaluate the accuracy of the asymptotical variance estimator of
our estimator in finite sample sizes.
4 · 1 Efficiency
In this subsection we investigate the statistical efficiency of the six methods: the proposed method
(MLE), CM, MHS, AP, PC and ZH methods for estimating α0 and α1 in the binormal model and
for estimating the corresponding ROC curve by numerical studies. We use the root of mean squared
error (RMSE) to measure the performance of the various estimators for α0 and α0 and the sum
of RMSEs for α0 and α1 as an overall performance measure. We evaluate the performance of an
estimator R̂OC(·) for the ROC curve using the average of squared errors (ASE), defined by
ASE =
1
ngrid
ngrid∑
k=1
{
R̂OC(uk)−ROC(uk)
}2
, (13)
where {uk, k = 1, · · · , ngrid} are the grid points at which the functions ROC(·) are estimated. In
the simulation studies, we choose ngrid = 100 and uk’s to be uniformly distributed over (0, 1). We
choose 500 simulations for each scenario. Data for non-diseased subjects are generated from the
standard normal distribution, and data for diseased subjects are generated from N(2, 1.44). We
choose sizes of the diseased and non-diseased samples to be both equal and unequal, (n0, n1) =
10
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{(100, 100), (200, 100), (200, 200)}, to investigate the effect of the sample sizes on the performance
of the estimates.
Table 1 gives bias, SD, RMSE and SRMSE of the resulting estimators for α0 and α1 by the six
methods. From Table 1 we see that in all cases, our new MLE has the smallest SRMSE and is the
best choice. Specifically, our MLE consistently has smaller bias, standard error, and RMSE than
the CM estimator due to a smaller number of nuisance parameters to estimate. Although the PC
can have the smallest variance, its bias is also large and can even be larger than its variance, which
means that the bias is significant and could not be ignored; the AP estimator is less biased than the
PC estimator but has a larger variance than the PC estimator. The ZH estimator has the largest
RMSE and bias.
Figure 1 depicts the distribution of the estimated ASE for the ROC curve over the 500 replications
for each method. The MLE and CM estimators have comparable ASE, which is smaller than the
other existing methods. The performance of the estimators MHS and AP is close to that of our
MLE in this setting. Further simulation study (not reported here) shows that when the accuracy of
a diagnostic test is not too high or the sample size is large so that In can be large, the computation
algorithm in the MHS method, which collapses too many jump points, can lead to some loss of
efficiency. The AP estimator has smaller ASE than the PC estimator, and the ZH estimator has the
largest ASE.
In summary, the existing CM, MHS, and AP estimators have similar efficiency as our ML estima-
tor with the ML estimators being slightly better. The ZH estimators have the worst performance.
4 · 2 Robustness
In the subsection, we compare the robustness of the six methods against the departure from the
binormal assumption.
One anonymous reviewer has suggested that it may be reasonable to expect a transforma-
tion to result in approximate normal data for non-diseased subjects, but since the population of
diseased subjects is often a mixture of subpopulations of subjects in different stages of the dis-
ease/infection, it seems much more reasonable to expect that transformation would result in a
11
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Table 1: Estimates of (α0, α1) compared with their actual values over the 500 replications
α0 = 2/1.2 α1 = 1/1.2
n0 n1 method Bias SD RMSE Bias SD RMSE SRMSE
100 100 MLE 0.038 0.209 0.212 0.012 0.137 0.137 0.349
CM 0.074 0.213 0.226 0.043 0.141 0.148 0.373
MHS 0.002 0.212 0.212 -0.033 0.142 0.146 0.358
AP 0.025 0.225 0.226 0.041 0.164 0.169 0.395
PC -0.105 0.169 0.199 -0.163 0.088 0.185 0.384
ZH 0.126 0.205 0.241 0.367 0.095 0.379 0.620
200 100 MLE 0.028 0.180 0.182 0.009 0.113 0.113 0.295
CM 0.039 0.184 0.188 0.022 0.115 0.117 0.305
MHS 0.022 0.208 0.209 -0.014 0.142 0.143 0.352
AP 0.027 0.191 0.193 0.034 0.131 0.136 0.328
PC -0.105 0.142 0.177 -0.129 0.092 0.158 0.335
ZH 0.128 0.168 0.211 0.288 0.063 0.295 0.506
200 200 MLE 0.016 0.140 0.141 0.002 0.093 0.093 0.234
CM 0.024 0.142 0.144 0.012 0.094 0.095 0.239
MHS -0.009 0.137 0.137 -0.014 0.102 0.103 0.240
AP 0.009 0.144 0.145 0.017 0.103 0.104 0.249
PC -0.108 0.123 0.164 -0.132 0.087 0.158 0.322
ZH 0.049 0.152 0.160 0.305 0.078 0.315 0.475
12
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mixture of normals rather than a single normal for diseased subjects. So, to investigate the robust-
ness of the binormal model, we simulate test responses of non-diseased subjects from N(0, 1), but
test responses of diseased subjects from the mixture of the two normal distributions, N(1.2, 1.22)
and N(2.2, 1.52), with the corresponding mixing proportions of 1/2 and 1/2, respectively. We set
(n0, n1) = {(100, 100), (200, 200)} to investigate the effect of the sample sizes on the performance of
the estimates.
Figures 2(A) and 3(A) plot the average of the estimated ROC curves over the 500 replications
for each method when the sample sizes are (100, 100) and (200, 200), respectively. Our MLE has the
smallest ASE and hence is the most robust estimate among the six ones considered here. The CM,
MHS and AP also have good robustness properties. The PC and ZH estimators have larger bias.
Figures 2(B) and 3(B) depict the distribution of the ASE for the estimated ROC curves over the
500 replications for each method when the sample sizes are (100, 100) and (200, 200), respectively.
The AP estimator has better ASE than the PC estimator, which means the AP estimator is more
robust than the PC estimator. The ZH estimator has the largest ASE.
We also conduct numerical studies with a larger number of the components in a normal mixture.
We generate test results of non-diseased subjects from the standard normal distribution but test re-
sults of diseased subjects from a mixture of the three normal distributions, N(1.2, 1.22), N(2.2, 1.52)
and N(2.2, 1), with the corresponding mixing proportions of 1/3, 1/3, and 1/3, respectively. The
results (not reported here) are similar to those in Figures 2 and 3 except that the PC estimator
seems to have the largest bias and ASE, suggesting that the robustness of the PC estimator may
decrease as the number of components in normal mixtures increases.
In summary, the existing CM, MHS, and AP estimators have similar robustness as our ML
estimators even though the ML estimators are slightly better.
4 · 3 Asymptotic inference in finite sample
Finally, we assess the accuracy of our variance estimator given in Section 3 in finite sample sizes. We
investigate the performance of our variance estimator using the simulated data in Sections 5.1 and
5.2. Based on 500 simulated data sets, we obtain 500 estimates of α̂0 and α̂1 and their corresponding
13
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Table 2: Average (SEave) and standard deviation (SEstd) of the standard error estimates over the
500 replications for the binormal simulated data in Section 4.1
α0 = 2/1.2 α1 = 1/1.2
n0 n1 SD SEave(SEstd) Coverage SD SEave(SEstd) Coverage
50 100 0.230 0.226(0.049) 0.939 0.160 0.161(0.043) 0.917
100 100 0.209 0.202(0.040) 0.920 0.137 0.133(0.031) 0.922
200 100 0.180 0.186(0.035) 0.931 0.113 0.113(0.024) 0.933
200 200 0.140 0.140(0.020) 0.947 0.093 0.091(0.015) 0.929
Table 3: Average (SEave) and standard deviation (SEstd) of the standard error estimates over the
500 replications for the mixture normal data in Section 4.2
α0 α1
n0 n1 k* SD SEave(SEstd) SD SEave(SEstd)
50 50 3 0.239 0.244(0.034) 0.159 0.167(0.036)
100 100 3 0.164 0.168(0.016) 0.111 0.113(0.018)
100 100 2 0.155 0.161(0.014) 0.097 0.105(0.015)
200 200 2 0.106 0.112(0.006) 0.068 0.071(0.007)
*where k is the number of terms in the mixture of normals for the diseased data.
standard error estimates using our method. From ML estimates of α0 and α1, we form the empirical
standard deviations, denoted by SD, which can be regarded as an approximation to the true standard
deviations. We denote the average and the standard deviation of 500 estimated standard errors for
the estimated α̂0 and α̂1 by SEave and SEstd, respectively, which summarize the overall performance
of the standard error estimator. We report our results in Table 2 for the simulated binormal data
and in Table 3 for the simulated mixture normal data, respectively. The standard error estimators
are very close to the ”true” sample standard errors. The empirical CI coverage probabilities are
close to their nominal levels.
14
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Figure 1: The distribution of ASE for the estimated ROC curves from the binormal model over the
500 replications.
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Figure 2: The diseased data are from a mixture of two normal distributions, but modeled with
the binormal model when n0 = n1 = 100. (A) The average of the estimated ROC curves; (B) the
distribution of ASE for the estimated ROC curves over the 500 replications.
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Figure 3: The diseased data are from a mixture of two normal distributions, but modeled with
the binormal model when n0 = n1 = 200. (A) The average of the estimated ROC curves; (B) the
distribution of ASE for the estimated ROC curves over the 500 replications.
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5 A real data example
In this section we illustrate the application of our newly proposed method in a real example on the
accuracy of biomarkers for detecting pancreatic cancer (Wieand et al., 1989). This study exam-
ined two biomarkers, the antigenic determinant, designated as CA125, and carbohydrate antigen
designated as CA19-9. The data consist of 51 measurements on subjects free of disease and 90
measurements on diseased subjects using the two biomarkers. Here, we used the results with CA125
to illustrate the application of our methodology.
Although the binormal ROC model (3) possesses a certain degree of robustness against normal
mixtures, as shown in the simulation study, it is also important to assess whether the binormal
model (3) is appropriate for the data before we make inferences on the ROC curve of the CA125
using the binormal model. Here, we present a graphical method to test model (3).
To detect any large discrepancies in fit, we compare the empirical ROC curve with the MLE of
the ROC curve obtained by substituting ML estimates of α0, α1 into model (3).
Figure 6(a) plots the empirical ROC curve, the maximum likelihood estimate of the ROC curve
and its 95% pointwise confidence intervals (denoted CI in Figure 6(a)), showing no obvious difference
between the empirical ROC curve and the estimated ROC curve based on the binormal model. So,
the binormal model is reasonable.
Table 4 lists the estimates for the coefficients α0 and α1 using the six methods. Both the PC
and ZH estimates are different from the others for the estimation of α0; ZH is very different with
the other for estimation of α1. These results are consistent with the simulation results, which have
shown that the PC and ZH estimates have large bias. Figure 6(b) plots the estimated ROC curves
using the six methods. The MLE, CM, and MHS estimates are quite similar and are distinct from
the others. We also note that the ZH estimate is substantially different from the rest.
6 Discussion
In this paper we have proposed a semi-parametric MLE for the ROC curve under the binormal ROC
curve model (3). The ML estimator is asymptotically normal. The asymptotic results also hold for
17
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Table 4: Estimates of (α0, α1) for CA125 as a diagnostic market of pancreatic cancer
method α̂0(SD) α̂1(SD)
MLE 1.192(0.158) 0.431(0.081)
MHS 1.177(0.160) 0.399(0.082)
CM 1.235(0.129) 0.480(0.074)
AP 1.142(0.153) 0.468(0.110)
PC 1.343(0.192) 0.490(0.040)
ZH 1.240(0.161) 0.911(0.048)
a more general specification of the parametric ROC curve model given by (2), for example, when G
and H are symmetric distributions and when H belongs to a location-scale family. Our simulation
results have indicated that the proposed ML estimators also have good finite-sample properties and
have similar efficiency and robustness as the existing CM, MHS, and AP estimators with the ML
estimators being slightly better than all the existing estimators considered here.
Hanley (1988) has shown that the binormal ROC curve model for ordinal-scale tests enjoys a
certain degree of robustness against departure from the bi-normality assumption. Our own sim-
ulation studies have also demonstrated this result. However, given limitations of any simulation
study, we want to emphasize that it is important to check the assumption of the bi-normality in any
application; for example one may use the graphical method suggested in Section 5.
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Appendix
We first define some additional notations that are needed to prove Conclusions 1-3. Define Dr =
(−1, Cr)T , D∗r = (−1, C∗r )T , Dr0 = (−1, Cr0)T , Dˇr = (−1, Cˇr)T and b0 = limn1/(n0 + n1).
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Figure 4: Estimated ROC curves using MLE, CM, MHS, AP, PC, and ZH for CA125 as a diagnostic
marker of pancreatic cancer.
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A.1 Proof of Conclusion 1
Let λn(θ,C∗) = 1n logLn, where Ln is defined by (8), C
∗ = (C∗1 , · · · , C∗I∗n−1)T , C∗r = g(Y ∗(r)), and
Y ∗(1) < · · · < Y ∗(I∗n) are distinct ordered test results of Y0i, i = 1, · · · , n0 and Y1j , j = 1, · · · , n1. It can
be shown that the MLE of θ and C∗ must satisfy the following equations:
∂λn(θ,C∗)
∂C∗r
=
1
n
(
k∗r
Φ(C∗r )− Φ(C∗r−1)
− k
∗
r+1
Φ(C∗r+1)− Φ(C∗r )
)
φ(C∗r )
+
1
n
(
`∗r
Φ(θTD∗r )− Φ(θTD∗r−1)
− `
∗
r+1
Φ(θTD∗r+1)− Φ(θTD∗r)
)
α1φ(θTD∗r ) = 0, (14)
for 1 ≤ r ≤ I∗n − 1, and
∂λn(θ,C∗)
∂θ
=
1
n
I∗n∑
r=1
`∗r
φ(θTD∗r )D∗r − φ(θTD∗r−1)D∗r−1
Φ(θTD∗r )− Φ(θTD∗r−1)
+
1
n
`∗1
φ(θTD∗1)D
∗
1
Φ(θTD∗1)
− 1
n
`∗I∗n
φ(θTD∗I∗n−1)D
∗
I∗n−1
1− Φ(θTD∗I∗n−1)
= 0, (15)
where k∗r = #{Y0i = Y ∗(r), i = 1, · · · , n0} and `∗r = #{Y1j = Y ∗(r), j = 1, · · · , n1}. If both Y ∗(r) and
Y ∗(r+1) correspond to non-diseased subjects, then `
∗
r = `∗r+1 = 0 , k
∗
r > 0 and k∗r+1 > 0. Hence,
from (14), we have k
∗
r
Φ(C∗r )−Φ(C∗r−1) =
k∗r+1
Φ(C∗r+1)−Φ(C∗r ) . Extending this argument to a sequence of M
contiguous jump points which only involve non-diseased subjects, we have
k∗r
Φ(C∗r )− Φ(C∗r−1)
= · · · = k
∗
r+M−1
Φ(C∗r+M−1)− Φ(C∗r+M−2)
,
which is equal to ∑r+M−1
j=r k
∗
j
Φ(C∗r+M−1)− Φ(C∗r−1)
.
Similar arguments indicate that for a sequence of M contiguous jump points which only involves
diseased subjects, we have
`∗r
Φ(θTD∗r )− Φ(θTD∗r−1)
= · · · = `
∗
r+M−1
Φ(θTD∗r+M−1)− Φ(θTD∗r+M−2)
,
which is equal to ∑r+M−1
j=r `
∗
j
Φ(θTD∗r+M−1)− Φ(θTD∗r−1)
.
Therefore, if we denote Y(1) < · · · < Y(In−1) to be the last points of contiguous sequences with same
disease statuses, and Cr = g(Y(r)), r = 1, · · · , In − 1, for 1 ≤ r ≤ In − 1, we can write (14) and (15)
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as
∂λn(θ,C∗)
∂Cr
=
1
n
(
kr
Φ(Cr)− Φ(Cr−1) −
kr+1
Φ(Cr+1)− Φ(Cr)
)
φ(Cr)
+
1
n
(
`r
Φ(θTCr)− Φ(θTCr−1) −
`r+1
Φ(θTCr+1)− Φ(θTCr)
)
α1φ(θTCr) = 0 (16)
and
∂λn(θ,C∗)
∂θ
=
1
n
In−1∑
r=2
`r
φ(θTDr)Dr − φ(θTDr−1)Dr−1
Φ(θTDr)− Φ(θTDr−1)
+
1
n
`1
φ(θTD1)D1
Φ(θTD1)
− 1
n
`In
φ(θTDIn−1)DIn−1
1− Φ(θTDIn−1)
= 0, (17)
respectively, where kr and `r are defined in Section 2. Note that (16) and (17) do not depend on
the nuisance parameters C∗r = g(Y
∗
(r))’s with Y
∗
(r) ∈ <. Hence Conclusion 1 follows.
A.2 Proof of Conclusion 2
The Hessian matrix corresponding to the log-likelihood function is tridiagonal; that is, the Hessian
matrix has nonzero entries only along its diagonal and in elements adjacent to its diagonal. If we
denote Q to be the (In − 1)× (In − 1) Hessian matrix, and z to be any (In − 1) dimensional vector,
we have
zTQz =
1
n
In−1∑
r=1
z2r
{
kr
φ′(Cr) (Φ(Cr)− Φ(Cr−1))− φ2(Cr)
(Φ(Cr)− Φ(Cr−1))2
− kr+1φ
′(Cr) (Φ(Cr+1)− Φ(Cr)) + φ2(Cr)
(Φ(Cr+1)− Φ(Cr))2
+α21`r
φ′(θTDr)
(
Φ(θTDr)− Φ(θTDr−1)
)− φ2(θTDr)
(Φ(θTDr)− Φ(θTDr−1))2
−α21`r+1
φ′(θTDr)
(
Φ(θTDr+1)− Φ(θTDr)
)
+ φ2(θTDr)
(Φ(θTDr+1)− Φ(θTDr))2
}
+
1
n
In−2∑
r=1
zrzr+1
{
kr+1
φ(Cr)φ(Cr+1)
(Φ(Cr+1)− Φ(Cr))2
+ α21`r+1
φ(θTDr)φ(θTDr+1)
(Φ(θTDr+1)− Φ(θTDr))2
}
+
1
n
In−1∑
r=2
zrzr−1
{
kr
φ(Cr)φ(Cr−1)
(Φ(Cr)− Φ(Cr−1))2
+ α21`r
φ(θTDr)φ(θTDr−1)
(Φ(θTDr)− Φ(θTDr−1))2
}
= $1 +$2 −$3.
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Some computations show that
$1 =
1
n
In−1∑
r=1
z2rφ
′(Cr)
{
kr
Φ(Cr)− Φ(Cr−1) −
kr+1
Φ(Cr+1)− Φ(Cr)
}
,
$2 =
1
n
In−1∑
r=1
z2rφ
′(θTDr)
{
α21`r
Φ(θTDr)− Φ(θTDr−1) −
α21`r+1
Φ(θTDr+1)− Φ(θTDr)
}
,
$3 =
1
n
{
In−1∑
r=1
(zrφ(Cr)− zr−1φ(Cr−1))2 kr
(Φ(Cr)− Φ(Cr−1))2
+
In−1∑
r=1
(
zrφ(θTDr)− zr−1φ(θTDr−1)
)2
α21`r
(Φ(θTDr)− Φ(θTDr−1))2
+
z2In−1kInφ
2(CIn−1)
(1− Φ(CIn−1))2
+ z2In−1
α21`Inφ
2(θTDIn−1)
(1− Φ(θTDIn−1))2
}
.
Note that kr =
∑n0
i=1 I(Cr−1 < g(Y0i) ≤ Cr) and `r =
∑n1
j=1 I(Cr−1 < g(Y1j) ≤ Cr), by the central
limit theorem, we can show that $1 = O(n−1/2) and $2 = O(n−1/2). Since $3 ≥ 0 and equals zero
if and only if z = 0, zTQz ≤ 0 and equals zero if and only if z = 0 when n is large enough. Therefore,
given θ, the log-likelihood function is a concave function of C, which implies that a unique maximum
exists.
A.3 Proof of Conclusion 3
Let Cˇ1 = C10+ ε for any ε > 0 and Cˇ2, · · · , CˇIn−1 be the solution to the first In− 2 score equations
in (10) given C1 = Cˇ1. Define Φˇr = Φ(Cˇr) for r = 1, · · · , In − 1. Let ΦˇIn be the solution to the
following equation:
Gn(x) ≡ kIn−1
φ(CˇIn−1)
Φ(CˇIn−1)− Φ(CˇIn−2)
− kIn
φ(CˇIn−1)
x− Φ(CˇIn−1)
+α1`In−1
φ(θT DˇIn−1)
Φ(θT DˇIn−1)− Φ(θT DˇIn−2)
− α1`In
φ(θT DˇIn−1)
x− Φ(θT DˇIn−1)
= 0.
Since
kr
n
− (1− b0)
[
Φ(Cr0)− Φ(C(r−1),0)
]
= Op(n−1/2) (18)
and
`r
n
− b0
[
Φ(θT0 Dr0)− Φ(θT0 Dr−1,0)
]
= Op(n−1/2), (19)
for 1 ≤ r ≤ In, we have
Gn(x) = gn(x) (1 + op(1)) , (20)
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where
gn(x) = (1− b0)φ(CˇIn−1)
[
Φ(CIn−1,0)− Φ(CIn−2,0)
Φ(CˇIn−1)− Φ(CˇIn−2)
− 1− Φ(CIn−1,0)
x− Φ(CˇIn−1)
]
+b0α1φ(θT DˇIn−1)
[
Φ(θTDIn−1,0)− Φ(θTDIn−2,0)
Φ(θT DˇIn−1)− Φ(θT DˇIn−2)
− 1− Φ(θ
TDIn−1,0)
x− Φ(θT DˇIn−1)
]
. (21)
Since Gn(ΦˇIn) = 0, we have
gn(ΦˇIn) = op(1). (22)
Furthermore, we have,
1
n
∂
∂CIn−1
log{Ln}|C=Cˇ
=
{
(1− b0)φ(CˇIn−1)
[
Φ(CIn−1,0)− Φ(CIn−2,0)
Φ(CˇIn−1)− Φ(CˇIn−2)
− 1− Φ(CIn−1,0)
1− Φ(CˇIn−1)
]
+b0α1φ(θT DˇIn−1)
[
Φ(θTDIn−1,0)− Φ(θTDIn−2,0)
Φ(θT DˇIn−1)− Φ(θT DˇIn−2)
− 1− Φ(θ
TDIn−1,0)
1− Φ(θT DˇIn−1)
]}
(1 + op(1))
= gn(1) (1 + op(1)) = gn(Φ(CIn,0)) (1 + op(1)) ,
where Cˇ = (Cˇ1, . . . , CˇIn−1). Hence, if the assumption that
Φˇr > Φ(Cr0) (23)
holds for r = In, by (22) and the fact that gn(x) is a strict increasing function of x, we obtain
1
n
∂
∂CIn−1
log{Ln}|C=Cˇ < 0
for any given ε > 0. Hence the second part of Conclusion 3 follows.
Now we prove that the assumption (23) holds for r = 2, · · · , In. We use the inductive method
to prove (23). The inductive method relies on In − 1 steps. The first step consists of an conclusion
for r = 2. From (10), we see that Cˇ2 satisfies
G1(x) =
1
n
∂
∂C1
log{Ln(θ,C)}|C1=Cˇ1,C2=x
=
k1
n
φ(Cˇ1)
Φ(Cˇ1)
− k2
n
φ(Cˇ1)
Φ(x)− Φ(Cˇ1)
+α1
`1
n
φ(θT Dˇ1)
Φ(θT Dˇ1)
− α1 `2
n
φ(θT Dˇ1)
Φ(θT x˜)− Φ(θT Dˇ1)
= 0. (24)
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By (18) and (19), we have
G1(x) = g1(x) (1 + op(1)) (25)
where
g1(x) = (1− b0)φ(Cˇ1)
{
Φ(C10)
Φ(Cˇ1)
− Φ(C20)− Φ(C10)
Φ(x)− Φ(Cˇ1)
}
+b0α1φ(θT Dˇ1)
{
Φ(θTD10)
Φ(θT Dˇ1)
− Φ(θ
TD20)− Φ(θTD10)
Φ(θT x˜)− Φ(θT Dˇ1)
}
,
and Dr = (−1, Cr)T . Thus by (24) and (25), we have g1(Cˇ2) = op(1). In addition, g1(C2) is an
increasing function of C2 and g1(C20) < 0 since Cˇ1 > C10. Hence
Cˇ2 > C20,
and (23) holds for r = 2.
The step j consists of showing that the conclusion (23) for r = j + 1 is true given that the
conclusions from the step 1, · · · , j. Using the same argument as before with r = 2, we can prove
(23) hold for r = j + 1 given Φˇr > Φ(Cr0), r = 2, · · · , j. Hence (23) hold for r ≤ In.
Using the same argument as before with Cˇ1 = C10+ε, we can obtain the first part of Conclusion
3.
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